WO2000051684A3 - Regulators of coenzyme-a-independent transacylase as psychotropic drugs - Google Patents

Regulators of coenzyme-a-independent transacylase as psychotropic drugs Download PDF

Info

Publication number
WO2000051684A3
WO2000051684A3 PCT/GB2000/000779 GB0000779W WO0051684A3 WO 2000051684 A3 WO2000051684 A3 WO 2000051684A3 GB 0000779 W GB0000779 W GB 0000779W WO 0051684 A3 WO0051684 A3 WO 0051684A3
Authority
WO
WIPO (PCT)
Prior art keywords
coenzyme
regulators
psychotropic drugs
independent transacylase
transacylase
Prior art date
Application number
PCT/GB2000/000779
Other languages
French (fr)
Other versions
WO2000051684A2 (en
Inventor
David Frederick Horrobin
Original Assignee
Scarista Ltd
Horrobin David F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scarista Ltd, Horrobin David F filed Critical Scarista Ltd
Publication of WO2000051684A2 publication Critical patent/WO2000051684A2/en
Publication of WO2000051684A3 publication Critical patent/WO2000051684A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Use of drugs which are able to inhibit CoAIT in the treatment of, or in the manufacture of a medicament for the treatment of psychiatric disorders.
PCT/GB2000/000779 1999-03-03 2000-03-03 Regulators of coenzyme-a-independent transacylase as psychotropic drugs WO2000051684A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9904895.1 1999-03-03
GBGB9904895.1A GB9904895D0 (en) 1999-03-03 1999-03-03 Regulators of coenzyme-A-independent transacylase as psychotropic drugs

Publications (2)

Publication Number Publication Date
WO2000051684A2 WO2000051684A2 (en) 2000-09-08
WO2000051684A3 true WO2000051684A3 (en) 2001-01-04

Family

ID=10848886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/000779 WO2000051684A2 (en) 1999-03-03 2000-03-03 Regulators of coenzyme-a-independent transacylase as psychotropic drugs

Country Status (2)

Country Link
GB (1) GB9904895D0 (en)
WO (1) WO2000051684A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289204A2 (en) * 1987-04-27 1988-11-02 Efamol Holdings Plc Lithium salt-containing pharmaceutical compositions
WO1993016674A1 (en) * 1992-02-11 1993-09-02 Smithkline Beecham Corporation CoA-IT AND PAF INHIBITORS
WO1997004765A1 (en) * 1995-07-25 1997-02-13 Smithkline Beecham Corporation INHIBITION OF CoA-INDEPENDENT TRANSACYLASE AND APOPTOSIS
WO1998016216A1 (en) * 1996-10-11 1998-04-23 Scotia Holdings Plc Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
WO1998048788A1 (en) * 1997-04-29 1998-11-05 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289204A2 (en) * 1987-04-27 1988-11-02 Efamol Holdings Plc Lithium salt-containing pharmaceutical compositions
WO1993016674A1 (en) * 1992-02-11 1993-09-02 Smithkline Beecham Corporation CoA-IT AND PAF INHIBITORS
WO1997004765A1 (en) * 1995-07-25 1997-02-13 Smithkline Beecham Corporation INHIBITION OF CoA-INDEPENDENT TRANSACYLASE AND APOPTOSIS
WO1998016216A1 (en) * 1996-10-11 1998-04-23 Scotia Holdings Plc Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
WO1998048788A1 (en) * 1997-04-29 1998-11-05 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1989, VADDADI K S ET AL: "A DOUBLE-BLIND TRIAL OF ESSENTIAL FATTY ACID SUPPLEMENTATION IN PATIENTS WITH TARDIVE DYSKINESIA", XP002148486, Database accession no. PREV198988008362 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, HORROBIN D F ET AL: "Possible relevance of phospholipid abnormalities and genetic interactions in psychiatric disorders: The relationship between dyslexia and schizophrenia.", XP002148483, Database accession no. PREV199698702575 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, PEET MALCOLM ET AL: "Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients.", XP002148485, Database accession no. PREV199598430715 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, ADAMS PETER B ET AL: "Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression.", XP002148482, Database accession no. PREV199698797851 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; February 1998 (1998-02-01), CORRIGAN F M ET AL: "Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content.", XP002148484, Database accession no. PREV199800266210 *
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, vol. 30, no. 2, February 1998 (1998-02-01), pages 197 - 207, ISSN: 1357-2725 *
JOURNAL OF PSYCHIATRIC RESEARCH, vol. 29, no. 3, 1995, pages 227 - 232, ISSN: 0022-3956 *
LIPIDS, vol. 31, no. SUPPL., 1996, pages S157 - S161, ISSN: 0024-4201 *
MEDICAL HYPOTHESES, vol. 45, no. 6, 1995, pages 605 - 613, ISSN: 0306-9877 *
PSYCHIATRY RESEARCH, vol. 27, no. 3, 1989, pages 313 - 324, ISSN: 0165-1781 *

Also Published As

Publication number Publication date
WO2000051684A2 (en) 2000-09-08
GB9904895D0 (en) 1999-04-28

Similar Documents

Publication Publication Date Title
MXPA03007712A (en) Pharmaceutical salts.
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
AP2004002982A0 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
WO2004021968A3 (en) Solution for ungual application
WO2003009838A1 (en) Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus
HK1064669A1 (en) Substituted 1-oxy-2,8-diaza-spiro Ä4,5Üdec-2-ene derivatives as medicaments for the treatment of pain.
YU82702A (en) Ortho-substituted anthranilic acid amides and their use as medicaments
YU7804A (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
WO2000067847A3 (en) Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders
WO2001098279A3 (en) Bis-arylsulfones
ZA200201788B (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
SI1268522T1 (en) Novel lhrh-antagonists, production and use thereof as medicament
EP1440689A3 (en) Treatment of neurotic disorders
WO2000064423A3 (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
AU2001260110A1 (en) Novel LHRH-antagonists, Production and Use Thereof as Medicament
AU2002365288A1 (en) Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases
WO2000051684A3 (en) Regulators of coenzyme-a-independent transacylase as psychotropic drugs
AU2003227593A1 (en) New analogs of nitrobenzylthioinosine
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
WO2000061125A3 (en) Osanetant in the treatment of mood disorders
WO2001034124A3 (en) Use of 5ht-1a-serotonine receptor agonists for treating genetic or functional rhythm disorders in the respiratory system
WO2003000269A3 (en) Novel use for pde 10a inhibitors
HK1050480A1 (en) Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase